Approval comes amid positive results of a single-arm trial, showing a complete response rate of 77% in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

In this Pharmaceutical Executive video interview, Jon Hamrick, Partner, Curatio Scientia Advisors and Jon Rawlson, President & Founder, Armory Hill Advocates, discuss what’s stopping companies from investing in covering state level legislation and regulations impacting patient services, access, and affordability.

Leaders in areas such as drug discovery, clinical development and market access will meet to discuss AI, failing life expectancy, and a new generation of talent.

LabConnect will utilize the consulting firm’s assets to improve its clinical trial services.

The new tests are reportedly more accurate at detecting early-stage pancreatic cancer.

The latest news for pharma industry insiders.

In an interview with Pharm Exec Associate Editor Don Tracy, Alessandro Zannini, Global After-Sales Manager, Stevanato Group discusses the benefits of generative artificial intelligence.

Per the agreement, Cellares will integrate and automate some of Bristol Myers Squibb’s CAR T-cell therapies into its Cell Shuttle program.

In this Pharmaceutical Executive video interview, Jon Hamrick, Partner, Curatio Scientia Advisors and Jon Rawlson, President & Founder, Armory Hill Advocates, discusses how they went about testing their various hypotheses for the 2023 Patient Access: State Legal and Regulatory Environment Survey and how they collected the data.

The latest news for pharma industry insiders.

The MagicTouch will be the focus of the Magical-ISR study.

Alder, CEO of Gain Therapeutics, discusses how the Magellan platform was used in the creation of GT-02287.

While human infections of the virus are rare, a strain recently appeared in dairy cows before infecting a human in Texas.

Acquisition includes rights to marketing in the European Economic Area, Thailand, South Korea, and other regions for oral treatment of mild to moderately severe dementia associated with Alzheimer disease.

Approval was based on positive data from Takeda’s Phase III VISIBLE 2 study, which displayed long-term clinical remission in approximately half of patients with Crohn disease receiving Entyvio.

Data from the Phase III ALINA trial show that Alecensa reduced the risk of disease recurrence or death by 76% vs. platinum-based chemotherapy in patients with completely resected IB to IIIA ALK-positive non–small cell lung cancer.

Rahman discusses the new opportunities that digital twins present to researchers.

Insight that can help smaller biotech companies prepare for commercialization in the world of big pharma.

The latest news for pharma industry insiders.

In an interview with Pharm Exec Associate Editor Don Tracy, Lene Oddershede, SVP, Natural & Technical Sciences, Novo Nordisk Foundation offers a synopsis of upcoming projects from the Novo Nordisk Foundation.

According to results of the study, 46% of patients with giant cell arteritis administered Rinvoq achieved sustained remission from weeks 12 to 52.

Importing drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides an update on the progress of Coya 302 as a treatment for ALS.

The council was established as part of NORD’s Project RDAC.

Unique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.